Did you know that as many as 1 in 4 men who receive negative biopsy results may still have prostate cancer?

A standard prostate biopsy only provides a limited evaluation of prostate health because it actually only samples less than 1% of the entire prostate gland. 3T Multi-Parametric MRI is the most accurate, least invasive method of prostate cancer detection because sampling of the actual tumor is done with live MRI targeting with tumor visualization.

At the Sperling Prostate Center, we continue to strive for perfection and have implemented a powerful new advanced diagnostic tool into our program by utilizing genomic testing in the appropriate setting.

ConfirmMDx Genomic analysis of prostate cancer works at the DNA level to help distinguish patients who have a true-negative biopsy from those who may have occult (hidden) or extremely early stage cancer.

This works by identifying the Field Effect—an epigenetic field or “halo” associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This epigenetic halo around a cancer lesion can be present despite having a normal appearance under the microscope or even at times on an MRI image. Since these changes appear only at the molecular level, they cannot be seen by the standard microscopic evaluation or even the most advanced mpMRI study.

When indicated, we utilize one or more other laboratory analysis processes to gain detailed genomic profile of an individual’s disease and risk level:

  • Oncotype Dx – Once a prostate biopsy has been done, the tissue samples can be used for this further analysis. Based on the activity of certain prostate cancer genes, Oncotype Dx assigns a Genomic Prostate Score. The score indicates the probability that, if left untreated, the cancer would progress and eventually spread. For patients considering Active Surveillance, as well as those who will be treated, this helps both patient and doctor make an informed choice.
  • ProstaVysion – This analysis also uses biopsy tissue to examine a sequence of certain genes. By determining the genetic aggression profile, it can help predict the risk of future growth and spread. In particular, patients considering Active Surveillance can be guided by the results of this profile.
  • Prolaris – Unlike gene sequencing, Prolaris calculates how fast the cancer cells are dividing as a measure of aggressiveness. Patients whose biopsy indicated low risk disease can benefit from this additional information. This analysis is also often used after radical prostatectomy, when the actual tumor and additional body tissue can be tested to predict the likelihood of cancer recurrence elsewhere in the body. For prostatectomy patients, it can help determine if additional treatment (e.g. radiation or hormones) is indicated after surgery.

For more information about this genomic prostate test, please contact us today to schedule a consulation and begin your path towards peace of mind.

The latest news

just published:

Sperling Medical Group announces a new specialized area of practice dedicated to Neuravive, a revolutionary, noninvasive treatment for Essential Tremor. Find out more »

Sperling Prostate Center Makes List of 10 Best Prostate Cancer Blogs Learn more »

Sperling Prostate Center Joins MR-Guided Focused Ultrasound Clinical Study. Find out more »

Dr. Sperling speaks at the WPBF 25 Health and Safety Festival with Dr. Mehmet Oz Find out more & watch video »

Dr. Sperling included as featured expert on Prostate.net. See Dr. Sperling's articles »